Exciting Developments in Alzheimer's Disease Treatment
In recent findings from the Phase 2 MINDFuL trial, INmune Bio Inc. (NASDAQ: INMB) showcased the potential of XPro™, a selective soluble TNF inhibitor, specifically in patients experiencing early stages of Alzheimer’s Disease (AD). The study focused on individuals exhibiting inflammation biomarkers, revealing encouraging insights about the treatment's effectiveness.
Although the modified intent-to-treat (mITT) population of 200 participants did not achieve the main cognitive goal, targeted analysis of a subgroup comprised of 100 amyloid-positive patients with two or more inflammation biomarkers highlighted a marked cognitive, behavioral and biological advantage of XPro™ over a placebo. This subgroup presents a promising avenue for further exploration in Alzheimer’s treatment.
Trial Highlights: Key Beneficial Outcomes
XPro™ demonstrated favorable tolerability and a safety profile even in higher-risk groups, such as those with the ApoE4 genotype, which is known to heighten Alzheimer's risk. Notably, no patients experienced ARIA-E or ARIA-H side effects, and the most prevalent adverse events were localized to injection sites.
Insights from the MINDFuL Trial
The MINDFuL trial was a double-blind, placebo-controlled study that examined XPro's ability to slow cognitive decline due to neuroinflammation. The participants were monitored over a 24-week period, with measurements focusing on cognitive changes, behavioral alterations, and biomarkers associated with Alzheimer's pathology.
Patients were randomly assigned to receive either XPro™ or placebo in a 2:1 ratio. The primary endpoint centered on cognitive improvements over six months, assessed through the Early Mild Alzheimer’s Cognitive Composite (EMACC). While the overall population did not meet this endpoint, the defined subgroup exhibited promising results, paving the way for potential therapeutic avenues.
Specific Findings from Amyloid-Positive Groups
Among the amyloid-positive participants with two or more biomarkers indicative of inflammation, the trial uncovered several notable findings:
- Cognitive Benefits: A significant clinical advantage for XPro™ over placebo was evident on the EMACC primary endpoint with effect sizes of 0.27. Additionally, favorable outcomes were recorded on the Neuropsychiatric Inventory with an effect size of -0.24.
- Biological Results: The treatment group experienced improvements in blood markers of pTau217, which is a robust measure of Alzheimer's-related pathology, achieving an effect size of -0.20.
- Safety Considerations: XPro™ was deemed well-tolerated, with no reports of ARIA-E or ARIA-H occurrences. While injection site reactions were common, they did not deter overall participation in the trial.
- Innovative Mechanism of Action: The results suggest that targeting neuroinflammation can serve as an effective treatment strategy for Alzheimer’s Disease, emphasizing the importance of inflammation as a focus in AD treatment development.
Future Steps for INmune Bio
As a result of these promising findings, INmune Bio aims to pursue Breakthrough Therapy designation with the FDA. Further plans include scheduling an End-of-Phase 2 meeting to define subsequent steps for a pivotal trial aimed at supporting XPro™ approval. Regulatory engagements are also on the agenda to facilitate this process internationally.
Key Leadership Insights
RJ Tesi, MD, the CEO of INmune Bio, remarked, “These results illuminate the potential benefits XPro™ holds for Alzheimer’s patients across diverse demographics and health backgrounds. Our data establishes a solid foundation to advance XPro™ as a potential treatment option.”
CJ Barnum, PhD, the VP of CNS Drug Development, added, “By targeting neuroinflammation, XPro™ could significantly abate disease progression and alleviate cognitive symptoms in Alzheimer’s patients, addressing crucial unmet medical needs.”
Frequently Asked Questions
What is the XPro™ treatment?
XPro™ is a selective soluble TNF inhibitor developed by INmune Bio, aiming to reduce neuroinflammation to benefit cognitive function in Alzheimer's patients.
What does the MINDFuL trial demonstrate?
The MINDFuL trial demonstrates that XPro™ may provide cognitive and behavioral benefits in specific subpopulations of Alzheimer's patients, especially those presenting with inflammation biomarkers.
What are the next steps for INmune Bio after this trial?
The company plans to submit for Breakthrough Therapy designation with the FDA and will engage in discussions to finalize plans for future pivotal trials.
How was the safety profile of XPro™ in the trial?
XPro™ was reported to be well-tolerated, with no serious adverse events related to ARIA-E or ARIA-H, showcasing its safety even among high-risk patients.
When will additional trial results be shared?
Further findings are expected to be presented at the Alzheimer’s Association International Conference at a later date, along with ongoing analyses from the study.
